항암화학요법제 투여중인 암환자의 빈혈에 대한 Recombinant Human Erythropoietin(Eprex)의 임상 효과

Abstract

Background: Patients with advanced cancer frequently experience clinically significant anemia, which is often exacerbated by myelosuppressive chemotherapy. Method : In an effort to evaluate a possible role for recombinant human erythropoietin(rHuEPO)in anemic patients with cancer receiving chemotherapy, we studied 160 anemic cancer patients receiving cyclic combination chemotherapy in prospective multicenter, randomized, oepn labeled, phase III study. Result : In the 90 patients analyzed to date, respond to rHuEPO therapy was assessed by measuring changes in hematocrit level, and transfusion requirements. Conclusion : We conclude the rHuEPO is safe and effective for reversing anemia related to chemotherapy for cancer.